Cardiovascular

Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction

Harvey White

HARVEY WHITE, Auckland City Hospital, New Zealand

REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007
Enoxaparin could be the new standard anti-thrombotic therapy for patients receiving fibrinolysis for ST elevation myocardial infarction. This finding is from the double-blind EXTRACT-TIMI 25 Trial which compared the low molecular weight heparin with unfractionated heparin and saw a consistent treatment superiority from enoxaparin with a reduction in repeat myocardial infarction and mortality. Sarah Maxwell spoke with the principal investigator Harvey White at the Auckland City Hospital in New Zealand.

Similar Interviews

  • Do Blood Transfusions Increase Mortality Risk in Patients with Acute Myocardial Infarction?
  • Vivek Rajagopal, The Cleveland Clinic Foundation, OH American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 973-234 Patients

  • Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial
  • Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study
  • Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007,

    Post a comment

    Subscribe to Audio Medica Podcast